Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $189.5 million.

  • ImmunityBio's Non-Current Assets fell 592.29% to $189.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $776.4 million, marking a year-over-year decrease of 511.62%. This contributed to the annual value of $198.3 million for FY2024, which is 571.43% down from last year.
  • As of Q3 2025, ImmunityBio's Non-Current Assets stood at $189.5 million, which was down 592.29% from $193.9 million recorded in Q2 2025.
  • ImmunityBio's Non-Current Assets' 5-year high stood at $229.9 million during Q1 2023, with a 5-year trough of $109.9 million in Q1 2021.
  • In the last 5 years, ImmunityBio's Non-Current Assets had a median value of $201.4 million in 2024 and averaged $188.1 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 7492.1% in 2022, then plummeted by 1085.49% in 2024.
  • Over the past 5 years, ImmunityBio's Non-Current Assets (Quarter) stood at $134.6 million in 2021, then soared by 64.81% to $221.8 million in 2022, then dropped by 5.15% to $210.4 million in 2023, then decreased by 5.71% to $198.3 million in 2024, then fell by 4.47% to $189.5 million in 2025.
  • Its last three reported values are $189.5 million in Q3 2025, $193.9 million for Q2 2025, and $194.6 million during Q1 2025.